Sulprofos, disulfoton, azinphos-methyl, methamidophos, trichlorfon, and tebupirimphos were screened for neurotoxic potential, in accordance with U.S. EPA (FIFRA) requirements. Each organophosphate was administered through the diet for 13 weeks to separate groups of Fischer 344 rats at four dose levels, including a vehicle control. For each study, 12 rats/sex/dietary level were tested using a functional observational battery (FOB), automated measures of activity (figure-8 maze), and detailed clinical observations, with half of the animals perfused at term for microscopic examination of neural and muscle tissues. Separate groups of satellite animals (6/sex/dietary level) were used to measure the effect of each treatment on plasma, erythrocyte (RBC), and brain cholinesterase (ChE) activity. The results show that measures of ChE activity were consistently the most sensitive indices of exposure and assisted in the interpretation of findings. All treatment-related neurobehavioral findings were ascribed to cholinergic toxicity, occurring only at dietary levels that produced more than 20% inhibition of plasma, RBC, and brain ChE activity. Neurobehavioral tests provided no evidence of additional cumulative toxicity after 8 weeks of treatment. The FOB and motor activity findings did not alter the conclusions and generally did not reduce the neurobehavioral no-observed-effect level (NOEL) for any of the six compounds, relative to the results from detailed clinical observations as conducted in these studies. The one exception occurred with tebupirimphos, where the NOEL for motor activity was one dose level lower than the NOEL for the FOB and clinical observations. These results support the value of detailed clinical observations to screen for the neurotoxic potential of organophosphates and a general standard of more than 20% inhibition of brain ChE activity for cholinergic neurotoxicity. © 1997 society of Toxicoio g5 .
1 Portions of this research were presented at the 7th International Toxicology Congress (1995) and the 35th Annual Meeting of the Society of Toxicology (1996) . 2 To whom correspondence should be addressed.
Organophosphates have been used for decades to control insect pests in agriculture and in the home. These insecticides exert toxicity to target and nontarget species through inhibition of acetylcholinesterase (EC 3.1.1.7; AChE) in nerve and muscle tissues. The resulting persistence of acetylcholine in cholinergic synapses leads to repetitive stimulation of muscarinic and nicotinic receptors in target tissues. At sufficiently high exposure levels, this produces clinical signs of cholinergic poisoning that are reversible with discontinuation of exposure (Ecobichon, 1996) . Noncholinergic neurotoxic effects are also associated with exposure to certain organophosphates (Davis et al. y 1985; Marrs, 1993) . The most well known is organophosphate-induced delayed (poly)neuropathy (OPIDN), an effect that is associated with the aging of neuropathy target esterase (NTE) and results in persistent or permanent debilitation (Johnson, 1990; Lotti, 1992) . Ocular toxicity also occurs following exposure to certain organophosphates (Boyes et al., 1994) . It is not known whether ocular toxicity is associated with inhibition of AChE.
In order to register an organophosphate for use as a pesticide, it is necessary to conduct an extensive battery of toxicology studies in various species (EPA/FIFRA, OECD, Japan/MAFF). This database for each pesticide active ingredient includes the results of studies following acute (oral, dermal, and inhalation) and subchronic (28-or 90-day) exposure, and for organophosphates it includes studies in hens to establish the potential for causing OPIDN. To register a pesticide for use on food products, it is also necessary to conduct chronic 1-or 2-year exposure studies in rodent (mouse and rat) and non-rodent (e.g., dog) species and to characterize developmental (rat and rabbit) and reproductive (two-generation; rat) toxicity. Common endpoints for these studies include weekly observations for clinical signs, weekly measurements of body weight and food consumption, periodic clinical chemistry and hematology determinations, and microscopic examination of tissues for pathology at study termination. This database is used to establish target organs, mechanisms of toxicity, and, ultimately, acceptable exposure limits for humans. However, these results are not widely available since they are generally not published in the peer-reviewed scientific literature.
In 1991, the U.S. Environmental Protection Agency (EPA) published new draft guideline requirements that are designed to screen pesticides for neurotoxic potential following acute and subchronic (13-week) exposure (EPA, 1991) . The purpose of these requirements is to supplement the information in the existing toxicology database to determine whether additional studies are needed at a second tier of evaluation to investigate neurotoxicity. Pesticides that were registered for use before the publication of these new requirements were prioritized for testing, with chemicals of classes that are considered neurotoxic (e.g., organophosphate, carbamate, organochlorine, and pyrethroid compounds) assigned the highest priority. Since cholinergic neurotoxicity with organophosphates is well established, the purpose of these studies with organophosphates is not to determine whether they are neurotoxic; rather, it is to determine whether the relatively specialized and objective tests that are included in the screening battery (i.e., the functional observational battery, an automated measure of motor activity, and microscopic examination of perfusion-fixed neural tissues) would detect novel neurotoxic effects or lower the no-observedeffect level (NOEL), relative to standard tests used in other toxicology studies. A lower NOEL provides added protection to the public through the use of lower acceptable exposure levels in a quantitative risk assessment.
From 1992 to 1994, our laboratory performed neurotoxicity screening studies with six organophosphate insecticides to support product registrations in the United States. These studies were conducted under standardized conditions, in accordance with the aforementioned EPA requirements. The compounds that were tested include phosphonate, phosphoramidothioate, and phosphorothioate insecticides with a variety of physicochemical properties ( Fig. 1 ) and a broad range of relative potencies for inhibition of ChE activity. These results are being published to supplement the paucity of data in the literature that addresses the neurobehavioral effects of organophosphates following prolonged oral exposure (D'Mello, 1993) and to evaluate the level of ChE inhibition that is associated with a biological effect. An additional purpose is to assess the relative value of FOB and motor activity tests for risk assessment and for estimating the neurotoxic potential of organophosphates, compared to more routine tests that are included in toxicology studies (clinical observations, standard micropathology, and measures of ChE activity).
METHODS

Compliance
The animal care procedures and room conditions were in accordance with accepted standards of laboratory animal care, in compliance with the "'Animal Welfare Act of 1966" (Public Law 89-544) and its amendments, as well as the Guide for Care and Use of Laboratory Animals (NIH Publication No. 86-23, revised 1985) . The facility is fully accredited by AAALAC, in addition to being a registered research facility with the USDA. All studies were conducted in compliance with the FIFRA Good Laboratory Practice Standards of 40 CFR Part 160 and the OECD Principles of Good Laboratory Practice, C(8l)30 (Final) Annex 2 (Paris, 1981 (Paris, , 1992 .
Animal Information
Male and female (nulliparous and nonpregnant) Fischer 344 CDF(F-344)/ BR rats from Sasco, Inc., (Madison, WI) were used in all studies. The study design for each organophosphate required a total of 144 rats (72 males and 72 females) that were 8 weeks of age at the start of treatment. Upon receipt, animals were placed into individual stainless steel, wire-mesh cages and maintained at ambient laboratory conditions of 18-26°C, 40-70% relative humidity, and a 12-hr light/dark cycle for 6 days prior to placement on study. Purina Mills Rodent Lab Chow 5001-4 in "etts" form and municipal tap water were provided for ad libitum consumption except during neurobehavioral testing, when only water was provided.
Each rat was identified by cage card and tail tattoo with a number that did not reveal the dietary level. This was done to permit the observers to remain "blind " with respect to the animal's dose assignment during the FOB. In addition, animals were assigned a number that specified the sex, dietary level, cage number, and study number. Following acclimation, animals were weighed and those with body weights more or less than 20% of the mean body weight for each sex were rejected. The remaining animals were screened for ophthalmic lesions. Those that were accepted for study use were assigned to a control group or one of three dietary levels in a random but balanced fashion in order that, for each sex, groups had comparable average body weights when treatment was initiated.
Analytical Chemistry
Analysis of feed, corn oil, and water. Feed (Purina Mills Laboratories Inc., St. Louis, MO) and corn oil (Hazleton Laboratories America Inc., Madison, WI) used in diet preparation were analyzed for contaminants, using the Certification Profile for Purina Mills Certified Lab Chows (Purina Mills, Inc., 1987 ) as a general standard by which to gauge acceptable levels. Municipal tap water was analyzed for contaminants by NUS Laboratories (Houston, TX) or Pace Inc. (Lenexa, KS).
Test substance analysis. All six test substances were provided by the sponsor (Bayer Corp., Agriculture Division, Kansas City, MO) as the technical grade material. Chemical identity and structure were confirmed by NMR/ MS analysis. The concentration of active ingredient (A.I.) in the test substance was measured within 6 months of initiation of dietary exposure and again after terminal euthanization to verify stability at storage conditions. Concentrations of the A.I. in the ration were measured by liquid-or gaschromatographic analysis. The stability and homogeneity of the A.I. in the feed were established by analysis of feed samples. The concentration of the A.I. was measured for the ration that was used during Weeks 1, 5-6, 10, and 14 of the study to determine the average dietary concentration. The average daily intake of A.I. (i.e., mg A.I. consumed/kg of body wt/day) was calculated using the following relationship: (/j.g A.I./g feed/1000) X (feed consumed (g/kg body wt/day)].
Dose Selection
The results from dietary studies that ranged from 3-weeks to I-year duration were used to establish three dose levels for each test substance. In accordance with the test guideline (EPA, 1991) , the highest dietary level was selected to produce clear evidence of toxicity (the maximum-tolerated dose: MTD) without mortality, the low dose was selected to produce no evidence of exposure or. alternatively, minimal inhibition of AChE activity, and an intermediate dose was chosen to produce some evidence of toxicity. FIG. 1. Common name, CAS number, octanol/water partition coefficient (at 20°C), and structural formula for the organophosphorus compounds that were tested in these studies.
For tebupirimphos and azinphos-methyl, these studies established that females were substantially more sensitive than males. Therefore, the middle and high doses were reduced accordingly for females.
Experimental Design
Route, dose, and number of animals. Four dose groups of 18 rats/sex/ dietary level received each test substance in the diet for 13 weeks. The main study groups consisted of 12 rats/sex/dietary level that were used for neurobehavioral testing, with half used for neuropathology. The remaining six rats/sex/dose level were assigned to satellite groups for ChE determinations. Corn oil was used as the vehicle for the test article at I % by weight of the diet. A given batch of feed was available for ad libitum consumption for 2 to 7 days prior to changing, depending on the stability of the test article in the diet. At that time, any uneaten feed was collected and weighed to determine food consumption and was then disposed of by incineration.
Clinical signs, body weights, and food consumption.
Individual body weight and feed consumption determinations were made weekly. Cage-side observations were conducted at least twice daily (once daily on holidays and weekends) for mortality or clinical signs of moribundity. Detailed clinical observations for toxic signs were carried out once each week. This examination was performed in a systematic fashion that proceeded from the least to most manipulative with respect to the animal. First, the animal was observed in its home cage prior to disturbance for overt signs, such as unusual posture, course tremors, gross muscle fasciculations, activity level, and stereotypic or highly unusual behaviors (e.g., writhing or self-mutilation). The tray located below the cage was also inspected to assess the consistency and relative amount of feces or unusual amount, color, and odor of urine. Second, the cage was opened for an unobstructed view and the animal was observed for signs including clonic or tonic movements (e.g., convulsions, tremors, muscle fasciculations), response to stimuli (e.g., by tapping on the cage or snapping fingers), piloerection, gait abnormalities, respiratory abnormalities, and level of activity. Next, the animal was gently grasped around the trunk and retrieved from its cage. It was then inspected systematically for general appearance (e.g., dehydrated or emaciated), for areas of coloration, and for the presence and color of stains and secretions. The eyes were examined for the extent of palpebral closure and pupil size and the mouth was inspected for broken teeth or malocclusion During handling, it was noted whether the rat felt cool-or hot-to-touch, had abnormalities in muscle tone or muscle mass, showed areas of alopecia, or had evidence of injury. The location, color, and approximate size of gross lesions were also noted. Finally, the animal was returned to its cage and, as necessary, encouraged to move about (e g., by tapping on the cage or moving the feeder). Animals were observed further for gait abnormalities, for response to stimuli, and for clonic or tonic movements.
FOB and Motor Activity
The FOB used in these studies closely follows the battery of tests described by Moser (1988 Moser ( , 1989 . Scoring criteria and explicitly defined scales were used to rank the severity of observations that do not readily lend themselves to quantitation. The procedures used to measure landing foot splay and grip strength are based on established methods (Edwards and Parker, 1977; Meyer et al., 1979) . The technicians who conducted the FOB were "blind" with respect to the animal's group assignment. Observations for all animals were performed by one observer throughout each study, with a second person performing the measurements (e.g., grip strength and foot splay).
The overall design of the FOB is to perform tests in a sequence that progresses from the least to most interactive with respect to the animal. The FOB begins by observing the animal in its home cage, prior to disturbance, to evaluate posture, gait, level of activity, the presence of clonic or tonic movements, or other unusual behaviors or overt toxic signs. Next, the rat's response to removal and handling is rated and the observer notes the presence of various clinical signs (e.g., salivation, lacrimation, staining, palpebral closure, pupil size, and muscle tone) and appearance. The animal is then placed onto an open field to observe posture, activity level, gait, tonic and clonic movements, the presence of stereotypic or unusual behaviors, and respiratory abnormalities. At the end of 2 min, the cumulative number of rearing events, urine pools, and fecal boli is recorded. The animal is then evaluated for its response to visual, auditory, and tactile (touch and tail pinch) stimuli. Finally, the aerial righting reflex is evaluated for evidence of impairment, and grip strength, landing foot splay, colonic temperature, and body weight are measured.
Motor activity was measured by testing animals individually for 90 min in the figure-eight maze. The figure-eight maze was selected as an established and widely used automated activity-measuring device that can demonstrate both increases and decreases in activity (Reiter, 1983) . Each maze consists of a series of interconnected alleys (approximately 10 X 10 cm in cross-section) converging on a central arena and covered by transparent acrylic plastic (Reiter et al., 1975) . Each maze has eight infrared emitter/ detector pairs (three in each of the figure eight alleys and one in each of the blind alleys) to measure activity; each time-a beam is interrupted, an activity count is registered. The floor of each maze rested above absorbent paper which was changed at the end of each day. A Columbus Instruments (Columbus. OH) Universal Maze Monitoring System and a personal computer were used for automated data collection. Broad-spectrum background noise (approximately 70dB(A)) was provided throughout the test to minimize acoustical variations during testing. A white-noise generator (Model S81 -02, Coulbourn Instruments) produced background noise that was amplified by an audio-mixer amplifier (Model S82-24, Coulbourn Instruments) and presented through four speakers (Realistic Minimus-7, Radio Shack) positioned around the test area. The uniformity of light intensity (±10 footcandles) over each of the mazes was verified using a portable light meter. Motor activity was measured by recording the number of beam interruptions that occurred during each 10-min interval of the 90-min test session. Habituation was evaluated as a decrement in activity through successive intervals of the test session.
Animals in the main study groups were tested using the FOB and motor activity on four occasions-once during the week prior to initiating the exposure and again during Weeks 4, 8, and 13. On the day prior to each test day, the appropriate animals were placed in the sequence that had been established for testing on that day. The dose group identifier was concealed at that time to ensure that testing would be conducted without knowledge of the group assignment. Animals were then transferred to the room where testing took place and allowed to acclimate with minimal disturbance until testing on the following day. The test room was a standard animal room that was maintained on the same light/dark cycle as the animal room, with tests conducted during the light phase. Sets of animals were evaluated individually using the FOB and then, approximately I hr (minimum) after the last animal in the set had finished being tested in the FOB, all rats were placed individually into mazes to measure activity.
The order of testing and assignment of animals to mazes were done in a semirandom (SAS Institute, Inc., 1990) order, such that groups were balanced across test times and test devices and no animal was tested more than once in the same maze. For each test week, testing was staggered over 2 days for each sex to accommodate the schedule for neurobehavioral testing. Males and females were tested on separate days, with the open field and mazes cleaned during the ensuing interval to reduce the residual scent from the other sex.
Ophthalmology
Preexposure and preterminal (Week 12) ophthalmic exams were conducted on study animals in a semidarkened room. This consisted of a comprehensive examination of both eyes in each animal using a slit lamp microscope and an indirect ophthalmoscope. The preexposure examination was used to establish the baseline condition for each animal and to select animals for the main study groups which were free of ophthalmological defects that could interfere with the interpretation of study results.
Clinical Pathology
Erythrocyte (RBC) and plasma chohnesterase (ChE) activities were measured by analysis of blood samples that were collected from the orbital plexus of nonfasted. satellite group animals prior to treatment and during Weeks 4 and 13 of exposure. Brain ChE activity was measured at term using whole-brain homogenate from each satellite animal. The method used for measuring ChE activity is a modification (Hackathorn et al., 1983; Brownson and Watts, 1973) of the Ellman Reference Method (Ellman et al., 1961) . In this modification, 6,6'-dithiodinicotinic acid (Brownson and Watts, 1973; Grassetti et al., 1969) was used as a coupling agent rather than the Ellman reagent 5,5'-dithiobis-2-nitrobenzoic acid in order to avoid hemoglobin interference. The laboratory instrument was zeroed against a reagent blank (buffer, substrate, and coupling agent) and for monitoring RBC ChE activity, a tissue blank (buffer, erythrocyte hemolysate. and coupling agent) was subtracted. The tissue blanks were used to correct for absorbance due to endogenous glutathione (Dass et al., 1994) .
Gross Pathology
Excluding satellite animals, all rats were subjected to a complete gross necropsy. This involved an examination of all organs, body cavities, cut surfaces, external orifices, and surfaces. Gross lesions in neural tissues were sampled for microscopic examination.
The first six males and six females from the main study group at each dose level were selected for perfusion and collection of tissues, with replacement, as necessary, if the perfusion was considered inadequate. These animals were deeply anesthetized using an lp dose (approximately 50 mg/kg) of sodium pentobarbital and then perfused via the left ventricle with a sodium nitrite (in phosphate buffer) flush followed by in situ fixation using 4% glutaraldehyde and 4% EM-grade formaldehyde in phosphate buffer. The entire brain and spinal cord, both eyes (with optic nerves) and selected (bilateral) peripheral nerves (sciatic, tibial, and sural), the gasserian ganglion, gastrocnemius muscle, and physical identifier (tail) were dissected from each animal and postfixed in 10% buffered formalin. The brain was weighed upon removal from the skull, prior to placement into formalin, and the braimbody weight ratio was calculated. The remaining rats in the main study group were examined for gross lesions following CO 2 asphyxiation.
Micropathology
The following tissues from the perfused control and high-dose animals were processed for microscopic examination. Coronal sections from eight levels of the brain, cross-and longitudinal-sections from three levels of the spinal cord (cervical, thoracic, and lumbar), and the cauda equina (longitudinal section only) were embedded in paraffin and examined utilizing hematoxylin and eosin (H&E) stain. Dorsal root ganglia (including dorsal and ventral root fibers), the gasserian ganglion, eyes, optic nerves, and gastrocnemius muscle were embedded in glycol methacrylate (GMA). GMA-embedded tissues were sectioned at 2-3 fim and stained using a modified Lee's stain. Peripheral nerve tissues were embedded in epoxy resin, cut at approximately 1 /im, and stained with toluidine blue. Additional sections from each region of the brain and spinal cord were stained using luxol fast blue/cresyl violet and Sevier-Munger stains.
The tissues from the high-dose animals were examined relative to those from the control groups If treatment-related lesions were evident, further analysis was performed at the next lower dietary level.
Statistical Analysis
Statistical evaluations were performed using software from either INSTEM Computer Systems (INSTEM) or SAS Institute, Inc (1990) . With the exception of Bartlett's test for homogeneity of variance, which was tested at p =s 0.001, the level used to establish statistical significance was p =s 0.05. In the event of unequal variances, data were analyzed using nonparametric statistical procedures (Kruskal-Wallis ANOVA followed by the Mann-Whitney U test for between-group comparisons). Continuous data were analyzed using an ANOVA, followed by Dunnett's test if a significant F-value was determined in the ANOVA. For the FOB, continuous data were analyzed using a repeated-measures ANOVA, followed by a one-way ANOVA if there was a significant interaction between dose group and test week. For weeks on which there was a significant treatment effect, Dunnett's test was applied to determine if any group was significantly different from the control. Categorical data collected in the FOB were analyzed in a similar manner, using General Linear Modeling or Categorical Modeling (CATMOD) procedures, with post-hoc comparisons using Dunnett's test or an analysis of contrasts, respectively (SAS Institute, Inc., 1990).
Measures of activity for the entire session and for each 10-min interval were analyzed using ANOVA procedures. Session activity data were analyzed using a repeated-measures ANOVA, followed by a one-way ANOVA if there was a significant interaction between treatment and test occasion. For weeks on which there was a significant treatment effect, Dunnett's test was used to determine if any group was significantly different from control. Interval data were subjected to a two-way repeated-measures ANOVA, using both test interval and test occasion as repeated measures, followed by a repeated-measures ANOVA to determine on which weeks there was a significant treatment by interval interaction. For those weeks, the data for each interval were analyzed using a one-way ANOVA to determine at which intervals there was a significant treatment effect. For those intervals, Dunnett's test was used to compare each group to the concurrent control.
RESULTS
Dosage, Body Weight, and Food Consumption
The average dosage, measured as daily intake (mg) of the A.I. in the feed per unit of body weight (kg), was calculated for each group of males and females (Table 1) . Since females consumed more feed per unit of body weight than males, they received a greater dosage than males at a given dietary concentration.
The effects of treatment on body weight and food consumption are summarized in Table 2 . In general, the highest dietary level of each compound reduced body weight in one or both sexes. For groups that were affected, body weight averaged from 5 to 15% less than controls for the duration of exposure. For compounds that affected body weight, food consumption was generally reduced, relative to controls, during the first 1 or 2 weeks of exposure and recovered, thereafter, to control levels. This transient reduction in food consumption resulted in significantly reduced body weight gain during the first 2 weeks, which typically sustained a lower average body weight for the remainder of the study. Two exceptions to this generalization involved sulprofos, which did not affect body weight or food consumption in either sex and methamidophos, which reduced body weight in males, without having an appreciable effect on food consumption, and increased food consumption in females over the course of the exposure period without affecting body weight. Other exceptions, where only one parameter was affected, represent instances in which the effect was minimal but statistically significant and small differences with the other parameter were not statistically significant. Table 3 lists all compound-related effects that were evident by detailed clinical observation or the FOB at any time during the study. These findings are grouped for convenience into general categories of neuromuscular, CNS activity, or autonomic effects, and provide a direct comparison of the results for these two tests. Large differences in potency were evident among the six compounds, with limited evidence of toxicity at the highest dietary level (2500 ppm) of trichlorfon and severe toxicity, including one death, evident at a dose of 16 ppm of disulfoton. Females had more toxic signs than males at a given dietary level or had comparable signs at a lower dose than males. This difference represents a combination of their being somewhat more sensitive than males and receiving a slightly higher dosage (mg/kg/day) than males at a given dietary concentration (ppm; see Table 1 ). The earliest treatment-related clinical signs with all six compounds were evident within the first 2 or 3 weeks of exposure " Based on the average analytically confirmed concentration of the active ingredient in the feed and the quantity (g) of feed consumed/kg of body weight.
Clinical Observations and FOB
and signs of toxicity generally persisted with continued exposure to the end of the study. Likewise, treatment-related effects with the FOB were generally evident for both sexes during Week 4, the first test occasion following the initiation of exposure, with comparable evidence of toxicity on subsequent test occasions (Weeks 8 and 13).
Treatment-related effects that were detected with the FOB were generally also evident by clinical observation. For example, muscle fasciculations, tremors, increased reactivity, and various stains were evident with both tests. On the other hand, there were instances in which tremors and decreased activity were evident only during open field observation with the FOB and increased reactivity was evident only in the home cage with detailed clinical observations. Other exceptions consist primarily of tests that were not included as clinical observations (e.g., grip strength and aerial righting). The remaining differences for individual compounds are mainly due to the tests being performed on different schedules (i.e., weekly for clinical observations and monthly for the FOB) and never on the same day. For example, some clinical signs (e.g., certain autonomic signs) resolved before the first FOB assessment following treatment, during Week 4 of exposure.
A comparison of the NOELs for clinical observations compared to the FOB provides a measure of the relative sensitivity of the two tests. Only two differences occurred; in both cases, the NOEL for the FOB in males was one dose level lower than that for clinical observations. However, the overall NOEL for the compound, which is based on the more sensitive gender, was not different for clinical observations and the FOB for any of these compounds. Thus, there was no practical difference in the sensitivity of these two tests for any compound.
Motor Activity
The group mean pretreatment values with each organophosphate provide a measure of the inherent variability of the test procedure. As a general guide, these results indicate that differences of less than 20% were within the range of normal variability for groups of this size. Therefore, differences from control that were less than 20% would generally not be considered biologically significant, regardless of statistical outcome. For these six studies, there were no examples where a difference of less than 20% was statistically significant. However, the use of this standard did affect the interpretation of differences that were greater than 20%. Where such differences appeared to be doseand time-related in appearance, relative to the onset of treatment, they were considered biologically significant, regardless of statistical outcome. FOB  ---2500  ------2500  --500  -----------2500  ---500  500   Methamidophos   Observation   60  NP  NP  -60  --60  60  60  -12  60  --NP  NP  -60  ----12  60  --1.0  1 0   FOB  60  60  60  -----12  12  -1.0  12  -60  -60  -----12 Cumulative activity for the 90-min test session was reduced at the highest dietary level with all six organophosphates (Fig.  2) . In some cases, apparent differences were not statistically significant for the session because of a significant interaction between treatment and test interval. Untreated females were much more active than males, and females were generally affected to a greater extent than males at a given dietary level. In all cases, the greatest effect occurred during Week 4 or Week 8, with a comparable or lesser difference from control on subsequent test occasions. Thus, there was no evidence of a further cumulative effect after 8 weeks of exposure.
The temporal characteristics of treatment-related effects on activity within the test session are evident by examination of the results by 10-min intervals. The results with tebupirimphos are shown (Fig. 3) to illustrate representative effects with these compounds. Activity was reduced, relative to controls, in a dose-related fashion during the first few intervals of the 90-min session, until the level of activity in control and treated groups decreased substantially with habituation. Treatments that reduced motor activity in this manner consisted of sulprofos (females at 250 ppm), tebupirimphos (males at 60 ppm and females at 12 and 40 ppm), disulfoton (males and females at 16 ppm), azinphos-methyl (males at 120 ppm and females at 90 ppm), trichlorfon (males and females at 2500 ppm), and methamidophos (males and females at 12 and 60 ppm).
The characteristic effect of treatment on habituation is also illustrated by these results (Fig. 3) . Treatments that reduced activity effectively reduced the magnitude of habituation by decreasing activity during the early intervals of the test session. This is due to the operational definition of habituation as a decrement in activity during the test session. However, other characteristics of habituation did not change and habituation was apparent for all studies, even at dietary levels of compounds that markedly reduced activity. Thus, habituation was not considered to have been affected by these treatments at any dietary level.
Cholinesterase Inhibition
All six organophosphates produced dose-related decreases in plasma, RBC, and brain ChE activities in both sexes (Fig.  4) . There was no difference in the magnitude of inhibition for RBC and plasma ChE following 4 or 13 weeks of exposure; thus, there was no additional cumulative effect on either measure after 4 weeks of exposure. A similar comparison cannot be made for brain ChE since it was measured only at study termination. In general, RBC ChE activity was inhibited to a greater extent than plasma ChE, and brain ChE was the least sensitive. With the exception of trichlorfon. the highest dietary level of each test substance inhibited RBC ChE from 84 to 100% and brain ChE from 54 to 87%. By comparison, the high dose (2500 ppm) of trichlorfon produced 44 and 76% inhibition of RBC ChE, with 29 and 64% inhibition of brain ChE in males and females, respectively. The results among these organophosphates demonstrate approximately a 60-fold difference in potency for inhibition of ChE activity. In addition, these results demonstrate that brain, RBC, and plasma ChE were reduced in females to a greater extent than males at a given dietary level. This difference in sensitivity supports the selection of lower doses for females than males for tebupirimphos and azinphosmethyl, since the magnitude of ChE inhibition at the middle and high dietary levels were comparable at the doses selected for males and females. However, to assess the actual difference in sensitivity, it is necessary to consider the actual dosage (mg/kg/day) consumed by females compared to males at a given dietary concentration. The highest dose of tebupirimphos did not produce greater inhibition of RBC ChE than the middle dose for either sex but did produce more inhibition of brain and plasma ChE. This is interpreted as a maximum level of RBC ChE inhibition with this organophosphate by dietary exposure.
Ophthalmology
All ophthalmologic findings were considered incidental and not related to treatment since they occurred with a comparable incidence and severity in control and treated animals. Incidental lesions in control and treated rats generally occurred at a low incidence and were minimal or mild in severity. These included examples of corneal opacity, corneal ulcer, corneal edema, corneal neovascularization, corneal scar, anterior synechia, iritis, iris scar, retinal degeneration, pale retina, chromodacryorrhea, cataract, hyphema, and phthisis bulbi. A focal corneal opacity was the most common incidental finding, was observed in both control and treated animals, and was generally minimal to slight in severity.
Gross Pathology and Brain Weight
There were no treatment-related gross lesions at terminal sacrifice and brain weight was not affected by any of these treatments.
Micropathology
Treatment-related microscopic lesions among these six studies were limited to only one lesion with one organophosphate. This involved minimal myelin degeneration in the dorsal and ventral spinal nerve roots from the cervical and lumbar spinal cord at the 2500 ppm dietary level of trichlorfon. Myelin degeneration appeared in 80% of the high-dose males and females examined as a segmental, ballooning separation of the myelin lamellae from scattered, individual, spinal nerve root axons, without secondary Wallerian-type degeneration of the axon cylinder. Myelin degeneration was limited to the spinal nerve roots, sparing the peripheral nerves (sciatic, tibial, sural) and spinal cord. A NOEL was established for neuropathology, with no lesions in the spinal nerve roots from males or females that received the next lower dose of 500 ppm trichlorfon.
Various incidental lesions that were unrelated to treatment were present in each study. These lesions occurred at a comparable incidence in control and high-dose animals and were generally minimal in severity. Incidental findings included the degeneration of scattered individual nerve fibers in the trapezoid body, spinal cord, and spinal nerve roots; swelling of solitary axons in various brain and spinal cord regions; corneal mineralization; ocular limbal microgranuloma; unilateral degeneration of the retina, optic nerve, and central optic pathways; and an epidermoid cyst in the spinal cord. Table 4 summarizes the results for all six organophosphates, showing which tests were affected at each dietary level. These results illustrate a dose-related increase in ChE inhibition and overt evidence of toxicity. Measures of brain, RBC, and plasma ChE were the most sensitive indices of exposure for all six compounds. Although RBC and plasma ChE tended to be somewhat more sensitive than brain ChE, no single measure was consistently the most sensitive. There was also no consistent difference in relative sensitivity among clinical observations, FOB, and motor activity. For example, motor activity was affected in females that received a dose of tebupirimphos that did not affect the other two neurobehavioral tests. By comparison, for females that received disulfoton, clinical observations and the FOB were affected at lower doses than motor activity. Moreover, doses that affected the FOB also produced effects that were evident as clinical observations in the more sensitive gender. Body weight was consistently among the least affected endpoints at a given dietary level. These combined results demonstrate that either females were consistently more sensitive than males or there was no substantive sex-related difference in sensitivity. The lowest dietary level was a NOEL for all neurobehavioral endpoints and, with some exceptions for plasma and RBC ChE, either was a NOEL for measures of ChE activity or produced minimal (i.e., <20%) inhibition.
Summary Analysis
DISCUSSION
Measures of ChE inhibition were consistently the most sensitive indices of exposure, with no evidence of toxicity unless there was more than 20% inhibition. This is consistent with the report of others that neurobehavioral effects (FOB and motor activity) are not evident at dosages of the organophosphate paraoxon that produce less than 20% inhibition (Padilla et ai, 1992) . Smaller differences from control were detected by statistical analysis, with RBC and plasma ChE tending to be more sensitive than brain ChE. Thus, these three measures proved to be sensitive biomarkers of exposure and assisted in the interpretation of test results by providing quantitative measures of exposure. However, RBC and plasma ChE provide only indirect evidence of neurotoxicity, since they have no known biological function (EPA, 1990) and their selective inhibition has no known biological effect (Padilla et ai, 1992) . Furthermore, it is difficult to extrapolate plasma ChE results from animals to humans, since the enzymes that constitute plasma ChE activity vary from species to species. In rats, plasma ChE activity is approximately 50% butyryl-and 50% acetyl-cholinesterase while in humans it is 100% butyrylcholinesterase (Traina and Serpietri, 1984; Padilla et ai, 1994) . On the other hand, inhibition of these enzyme activities may predict AChE activity in brain and/or muscle tissue, especially under the conditions of these studies, where rapid changes are not expected (Padilla et ai, 1994) . By comparison, brain ChE is the enzyme that degrades acetylcholine in the brain and provides a direct measure of organophosphate effects in a critical "target tissue." Therefore, measures of brain ChE inhibition are directly relevant to neurotoxicity risk assessment. The present results indicate that levels of brain ChE inhibition that exceed 20% are associated with an adverse effect while lower levels of inhibition are not.
A determination of the cumulative effect of organophosphates on ChE activity is useful for risk assessment and for determining whether a study with a longer duration of exposure is warranted to investigate cholinergic neurotoxicity. The results with these six compounds demonstrate that there is no additional cumulative effect on RBC or plasma ChE after 4 weeks of exposure. The results from these studies do not provide a comparable determination of cumulative inhibition for brain ChE, since brain ChE was measured only at study termination (Week 13). However, the results from chronic toxicity studies in rats demonstrate no further effect on brain ChE from 13 weeks to 1 or 2 years of dietary exposure (unpublished results from this laboratory). This indicates that studies with a longer exposure period are not needed to characterize chronic cholinergic neurotoxicity.
Compound-related clinical signs in these studies ranged from minimal effects with the high dose of trichlorfon to severe toxic signs, including one death with disulfoton. This range of effects primarily reflects the difference in the magnitude of ChE inhibition with the high dose of these compounds. In spite of this difference, it is evident in each instance that these represent cholinergic signs, based on the combination of findings, compared to typical cholinergic signs that are associated with organophosphates (Ecobichon, 1996) , and based on their relationship to the level of ChE inhibition at a given dietary level.
The FOB findings were consistent, but not identical, with clinical signs and the results of both tests corresponded to the level of ChE inhibition. In general, endpoints that these two tests have in common produced comparable findings using these tests. Both clinical observations and the FOB detected cholinergic neuromuscular and autonomic effects, as well as effects on CNS activity. However, there were some differences in test results. Reduced activity and tremors were evident using both tests but there were examples where these effects were evident only with the FOB, during observation in the open field. This difference may be due to the relatively higher level of activity of control animals in the open field, compared to the home cage, affording a better circumstance for detecting a decrease in activity, and observing animals for an extended period in an environment where they are more available for detailed examination. Increased reactivity, on the other hand, was evident by detailed clinical observations in the home cage with some treatments where no difference was evident using the FOB. This difference in test results may be due to the emphasis of this test on observation of the animals in their home cage, prior to their being disturbed. The remaining differences were generally due either to the FOB including endpoints that are not included as clinical observations or to the tests being performed on different days and at different intervals. Effects that were evident only in the FOB included reduced forelimb grip performance with tebupirimphos, disulfoton, azinphosmethyl, and methamidophos, and an impaired aerial righting response with tebupirimphos, disulfoton, trichlorfon, and azinphos-methyl.
In the context of a screen for neurotoxicity, it is relevant to determine whether these differences represent cholinergic or noncholinergic effects. A reduction in forelimb grip performance, in the absence of an effect on hindlimb grip performance, is distinct from the preferential effect on hindlimbs that is associated with compounds (e.g., acrylamide and 2,5-hexanedione) that produce a distal axonopathy (Shell et al., 1992) . Thus, it is inconsistent with OPIDN. In contrast to the present results, treatments that produce OPIDN in rats preferentially affect the hindlimbs and cause debilitation that gets progressively worse with continued treatment, and the resulting debilitation is associated with characteristic microscopic lesions in the spinal cord and peripheral nerves (Veronesi, 1984; Padilla and Veronesi, 1988; Ehrich etal., 1995) . Many factors related to cholinergic toxicity (e.g.. autonomic FIG. 4. Brain (BChE) . erythrocyte (RChE). and plasma (PChE) cholinesterase results for male and female rats treated with ( Table 4 . or neuromuscular effects) could be involved. Thus, reduced forelimb grip performance in these examples is ascribed to cholinergic toxicity that would be expected to recover fully when exposure is discontinued. Similarly, impaired aerial righting occurred only in the presence of signs of cholinergically mediated neuromuscular impairment (e.g., muscle fasciculations, tremors, and/or gait incoordination), with substantial ChE inhibition. Therefore, this is also ascribed to cholinergic toxicity.
While the results from either clinical observations or the FOB were sufficient to establish that these findings reflect cholinergic toxicity, there may be circumstances where the additional results from the complement of tests that are included in an FOB would be necessary to distinguish one clinical syndrome from another. In particular, the additional information from the FOB might be needed to make such a determination if the underlying mechanism of action for the test substance were not known and/or if there were no biomarker of exposure comparable to measures of ChE activity. Furthermore, differences in procedures, such as the design of the FOB and level of detail for clinical observations, could affect the need for an FOB in addition to detailed clinical observations. Thus, these results do not rule out the added utility of an FOB under different circumstances.
The effect of these six compounds on activity in the figure-eight maze consisted of a reduction in activity, relative to controls, during the early intervals of the test session, before the activity of all groups decreased to low levels with habituation. This treatment-related effect did not affect the overall interpretation relative to other test results, since it was consistent with signs of decreased activity that were evident by observation in the open field (FOB) at these dietary levels with sulprofos, disulfoton, and methamidophos. On the other hand, decreased activity was apparent only by measurement in the figure-eight maze for tebupirimphos, azinphos-methyl, and trichlorfon and was evident in the maze at a lower dose with methamidophos than by observation. Thus, this automated measure of activity was generally more sensitive than observation for the detection of decreased activity. However, there was generally no practical difference in the sensitivity of these three tests, since the NOEL for activity in the maze was comparable to the overall NOEL for the FOB and clinical observations. The one exception occurred with tebupirimphos, where the NOEL for motor activity was one dose level lower than the NOEL for clinical observations and the FOB.
The detection of reduced motor activity is consistent with the findings of others who tested organophosphates following acute or repeated exposure (Lynch et al., 1986; Llorens et al., 1993) . The effect of these organophosphates on motor activity in the present studies may represent a centrallymediated cholinergic effect (Lynch et al., 1986) . On the other hand, since reduced activity occurs with a variety of neurotoxic and nonneurotoxic treatments (Gerber and O'Shaughnessy, 1986) , this effect with prolonged dietary exposure to organophosphates could represent nonspecific toxicity. Regardless of the underlying mechanism, the treatment-related reduction in activity was consistently greatest during Weeks 4 or 8 of exposure, with no additional cumulative effect thereafter. This outcome indicates that continued exposure after 13 weeks would not reveal either a novel effect on motor activity or a further reduction in the NOEL for this parameter.
Treatments that affected body weight in these studies caused reduced body weight gain at the highest dietary levels. Reduced weight gain was generally associated with a reduction in food consumption when the treated feed was first introduced to the animals. These examples of reduced food consumption could be due to the treated feed being unpalatable at the highest concentration of the organophosphate or could represent a manifestation of toxicity such as reduced appetite or increased gastric motility associated with cholinergic stimulation. It is considered less likely that this is due to the diet being unpalatable since the effect with various organophosphates was much more closely associated with the level of ChE inhibition than with the concentration of the compound in the diet. In any case, the animals adapted soon thereafter to consume feed and gain weight at a rate that was comparable to controls.
The extensive collection of tissues that was examined in these studies provided a more complete assessment of neuropathology than is available in standard toxicology studies that are conducted for pesticide registration. This difference resulted in the identification of a subtle, localized lesion as a new finding with exposure to a high dose of trichlorfon. This lesion consisted of minimal demyelination in spinal nerve roots in some high-dose animals, relative to concurrent controls. The reason that this lesion was not detected in other subchronic and chronic dietary studies at this dietary level is likely due to its limited distribution, involving a tissue that is not systematically examined. This lesion would also be less evident under conditions where the incidence of background lesions in control rats was higher, such as occurs with advanced age at the termination of a chronic study (unpublished observation from this laboratory) or with poor fixation. Other microscopic lesions that were evident in neural tissues from control and treated rats are consistent with spontaneous alterations reported by others (Eisenbrandt et al., 1990; Kulwich, 1994; Levine, 1966) .
The mechanism by which trichlorfon produced this lesion is not known. It is not attributed to ChE inhibition, since it did not occur with any other organophosphate, each of which produced higher levels of inhibition than trichlorfon at the highest dietary concentration. Furthermore, it is not attributed to OPIDN, since the nature (myelin vs the axon) and distribution of this lesion are distinct from the central-peripheral distal axonopathy that characterizes OPIDN (Veronesi, 1984; Padilla and Veronesi, 1988; Ehrich et al., 1995; Dyer et ai, 1992; Inui et al., 1993) . Since the axon was preserved in the affected fibers, this lesion is considered reversible (Spencer and Schaumburg, 1980) . The minimal nature of the lesion is consistent with it representing a subclinical (i.e., asymptomatic) condition. For risk assessment, it is relevant to consider that the results from a chronic toxicity study established that the criteria for a maximum-tolerated-dose (MTD) were achieved at a dietary level of 1750 ppm, while 2500 ppm exceeded the MTD (EPA, 1992) . Moreover, the 500-ppm dietary level was a NOEL for neuropathology and the overall NOEL was 100 ppm, based on 20% inhibition of ChE activity. Thus, neuropathology occurred only at a dietary level that was 25 times higher than the NOEL used for establishing acceptable margins of exposure. A lesion that occurs only at such a high dose is of no practical concern for risk assessment, since it is not used to establish safe levels of human exposure.
The ophthalmic exam and microscopic examination of associated tissues at the end of the exposure period revealed no compound-related lesions. Thus, there was no evidence of ocular toxicity with these organophosphates. Ophthalmic lesions that did occur in control and treated rats are consistent with incidental lesions reported by others (Bruner et al., 1992; Lee et al., 1990; Losco and Troup, 1988) . The absence of ocular toxicity with these organophosphates is consistent with the results of other subchronic and chronic toxicity studies performed for product registration (unpublished results from this laboratory). The adequacy of the procedures employed in these standard chronic toxicity studies for the detection of ocular lesions is supported by the detection of ocular lesions with other organophosphates (Boyes et al., 1994) .
In conclusion, this paper examines the results from subchronic neurotoxicity screening studies with a variety of organophosphate insecticides. Prolonged dietary exposure with each organophosphate produced biochemical and neurobehavioral evidence of cholinergic toxicity, with neurobehavioral effects evident only when there was more than 20% inhibition of ChE activity. There was no additional cumulative effect on ChE activity or neurobehavioral endpoints after 4 or 8 weeks of exposure, respectively. The FOB and automated test of activity provided additional information that complemented the other test results. However, the results from those tests were of limited value in these studies as components of a screen for neurotoxicity, since they provided no additional information that was of practical use for risk assessment relative to detailed clinical observations and measures of ChE inhibition. This outcome supports the value of detailed clinical observations from other toxicology studies in assessing the neurotoxic potential of an organophosphate. The additional value of the neuropathology procedures that were used in these studies is less clear. While a new lesion was detected, this occurred only with one compound, at a dose that exceeded the MTD; thus, this finding did not affect either the NOEL or the interpretation of neurotoxic potential with any of these compounds. As a screen for neurotoxic potential, the combined results with these organophosphates provide no evidence to support the need for additional studies to investigate neurotoxicity.
